SCHEMBL2940766

SCHEMBL2940766

Cn1cc(C=CC(=O)O)c2ccccc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.76
KMT2A Q03164 7/20 0.76
MAPT P10636 5/20 0.76
RAB9A P51151 3/20 0.76
NPC1 O15118 3/20 0.76
CASP3 P42574 1/20 0.76
SENP8 Q96LD8 1/20 0.76
SENP7 Q9BQF6 1/20 0.76
SENP6 Q9GZR1 1/20 0.76
ALDH1A1 P00352 4/20 0.60
IMPDH2 P12268 1/20 0.60
POLB P06746 3/20 0.50
NR4A2 P43354 1/20 0.50
GAA P10253 3/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HPGD P15428 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940762 1.00 MEN1 (0.76) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL11101952 0.89 KMT2A (0.62) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL8494191 0.89 KMT2A (0.73) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL8494188 0.89 KMT2A (0.73) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL14756766 0.87 MAPT (0.71) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL23046854 0.86 KMT2A (0.69) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL17529416 0.86 KMT2A (0.69) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL23046856 0.85 KMT2A (0.68) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL22713034 0.84 KMT2A (0.68) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL23600586 0.83 MEN1 (0.66) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 EP disclosed
EP-2435407-B1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2019-12-25 EP disclosed
US-9522140-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2016-12-20 US disclosed
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2015-11-12 US disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 US disclosed
US-8906952-B2 Indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY (KR) 2014-12-09 US disclosed
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2014-02-27 US disclosed
WO-2010137351-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2010-12-02 WO disclosed
US-20030087949-A1 Indolylpyrrole derivatives and cell death inhibitors SAGAMI CHEMICAL RESEARCH CENTER (JP) 2003-05-08 US disclosed
EP-1275646-A1 INDOLYLPYRROLE DERIVATIVES AND CELL DEATH INHIBITORS SAGAMI CHEMICAL RESEARCH CENTER (JP) 2003-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H MEN1 3656/4885KMT2A 1762/4885MAPT 2659/4885
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient DGAT2, DGAT1, DLAT MEN1 3352/4885KMT2A 659/4885MAPT 1593/4885
US-20030087949-A1 Indolylpyrrole derivatives and cell death inhibitors AIFM1, BAX, CASP3 MEN1 3615/4885KMT2A 3672/4885MAPT 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.